However, the detection of high-titer GAD65 autoantibodies in the serum and/or CSF of neurologic patients is not sufficient for a diagnosis of GAD65 autoimmunity in the absence of one of the compatible clinical phenotypes of stiff-person spectrum, autoimmune ataxia or autoimmune epilepsy. This evidence concerns the gene GAD2 and Autoimmunity.